|
1
|
Nathan H, Pawlik TM, Wolfgang CL, Choti
MA, Cameron JL and Schulick RD: Trends in survival after surgery
for cholangiocarcinoma: A 30-year population-based SEER database
analysis. J Gastrointest Surg. 11:1488–1497. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
WHO classification of tumours editorial
board. Digestive system tumours, . WHO Classification of Tumours.
1. 5th edition. International Agency for Research on Cancer; Lyon:
2019
|
|
3
|
Lee SW, Kim HJ, Park JH, Park DI, Cho YK,
Sohn CI, Jeon WK and Kim BI: Clinical usefulness of
18F-FDG PET-CT for patients with gallbladder cancer and
cholangiocarcinoma. J Gastroenterol. 45:560–466. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee Y, Yoo IR, Boo SH, Kim H, Park HL and
Hyun OJ: The role of F-18 FDG PET/CT in intrahepatic
cholangiocarcinoma. Nucl Med Mol Imaging. 51:69–78. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson CD, Rice MH, Pinson CW, Chapman
WC, Chari RS and Delbeke D: Fluorodeoxyglucose PET imaging in the
evaluation of gallbladder carcinoma and cholangiocarcinoma. J
Gastrointest Surg. 8:90–97. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruys AT, Bennink RJ, van Westreenen HL,
Engelbrecht MR, Busch OR, Gouma DJ and van Gulik TM: FDG-positron
emission tomography/computed tomography and standardized uptake
value in the primary diagnosis and staging of hilar
cholangiocarcinoma. HPB (Oxford). 13:256–262. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kitamura K, Hatano E, Higashi T, Seo S,
Nakamoto Y, Narita M, Taura K, Yasuchika K, Nitta T, Yamanaka K, et
al: Prognostic value of (18)F-fluorodeoxyglucose positron emission
tomography in patients with extrahepatic bile duct cancer. J
Hepatobiliary Pancreat Sci. 18:39–46. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma KW, Cheung TT, She WH, Chok KSH, Chan
ACY, Dai WC, Chiu WH and Lo CM: Diagnostic and prognostic role of
18-FDG PET/CT in the management of resectable biliary tract cancer.
World J Surg. 42:823–834. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cho KM, Oh DY, Kim TY, Lee KH, Han SW, Im
SA, Kim TY and Bang YJ: Metabolic characteristics of advanced
biliary tract cancer using 18F-fluorodeoxyglucose
positron emission tomography and their clinical implications.
Oncologist. 20:926–933. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Furukawa H, Ikuma H, Asakura K and Uesaka
K: Prognostic importance of standardized uptake value on F-18
fluorodeoxyglucose-positron emission tomography in biliary tract
carcinoma. J Surg Oncol. 100:494–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee JY, Kim HJ, Yim SH, Shin DS, Yu JH, Ju
DY, Park JH, Park DI, Cho YK, Sohn CI, et al: Primary tumor maximum
standardized uptake value measured on
18F-fluorodeoxyglucose positron emission
tomography-computed tomography is a prognostic value for survival
in bile duct and gallbladder cancer. Korean J Gastroenterol.
62:227–233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park MS and Lee SM: Preoperative
18F-FDG PET-CT maximum standardized uptake value
predicts recurrence of biliary tract cancer. Anticancer Res.
34:2551–2554. 2014.PubMed/NCBI
|
|
13
|
Paudyal B, Oriuchi N, Paudyal P, Higuchi
T, Nakajima T and Endo K: Expression of glucose transporters and
hexokinase II in cholangiocellular carcinoma compared using
[18F]-2-fluro-2-deoxy-D-glucose positron emission tomography.
Cancer Sci. 99:260–266. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Glazer ES, Liu P, Abdalla EK, Vauthey JN
and Curley SA: Neither neoadjuvant nor adjuvant therapy increases
survival after biliary tract cancer resection with wide negative
margins. J Gastrointest Surg. 16:1666–1671. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumors. 8th edition.
Wiley-Liss; New York, NY: 2017
|
|
16
|
Gallagher BM, Fowler JS, Gutterson NI,
MacGregor RR, Wan CN and Wolf AP: Metabolic trapping as a principle
of oradiopharmaceutical design: Some factors resposible for the
biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med.
19:1154–1161. 1978.PubMed/NCBI
|
|
17
|
Ikeno Y, Seo S, Iwaisako K, Yoh T,
Nakamoto Y, Fuji H, Taura K, Okajima H, Kaido T, Sakaguchi S and
Uemoto S: Preoperative metabolic tumor volume of intrahepatic
cholangiocarcinoma measured by 18F-FDG-PET is associated
with the KRAS mutation status and prognosis. J Transl Med.
16:952018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kubo Y, Aishima S, Tanaka Y, Shindo K,
Mizuuchi Y, Abe K, Shirabe K, Maehara Y, Honda H and Oda Y:
Different expression of glucose transporters in the progression of
intrahepatic cholangiocarcinoma. Hum Pathol. 45:1610–1617. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Semenza GL: Regulation of physiological
responses to continuous and intermittent hypoxia by
hypoxia-inducible factor 1. Exp Physiol. 91:803–806. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Semenza GL: Regulation of tissue perfusion
in mammals by hypoxia-inducible factor 1. Exp Physiol. 92:988–991.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ikeda E: Cellular response to tissue
hypoxia and its involvement in disease progression. Pathol Int.
55:603–610. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaymak ZA, Karahan N, Erdoğan M, Erdemoğlu
E, Zihni İ and Şengül SS: Correlation of 18F-FDG/PET
SUVmax, SUVmean, MTV, and TLG with HIF-1α in
patients with colorectal cancer. Mol Imaging Radionucl Ther.
30:93–100. 2021. View Article : Google Scholar : PubMed/NCBI
|
